Contemporary use of perioperative cisplatin‐based chemotherapy in patients with muscle‐invasive bladder cancer
Open Access
- 9 September 2010
- Vol. 117 (2), 276-282
- https://doi.org/10.1002/cncr.25429
Abstract
BACKGROUND: Level I evidence indicates that neoadjuvant cisplatin‐based chemotherapy, in combination with radical cystectomy (RC), is associated with a significant survival advantage for patients with muscle‐invasive bladder cancer. Despite this, neoadjuvant chemotherapy is not uniformly used. Our objective was to determine the patterns of utilization of neoadjuvant chemotherapy in patients undergoing RC for muscle invasive bladder cancer in a contemporary cohort in a tertiary care center. METHODS: A retrospective review was performed of patients with bladder cancer who underwent RC between 2003 and 2008 at our institution. Clinical stage, pathologic stage, renal function, and perioperative chemotherapy treatments were tabulated. Primary outcome measures were the type and use of neoadjuvant chemotherapy among eligible patients. Secondary measures were the utilization patterns of adjuvant chemotherapy, renal function, pathologic outcomes, and disease specific and overall survival. Reasons for nonutilization of chemotherapy were also examined. RESULTS: Among 238 patients who underwent RC for bladder cancer, 145 had a preoperative clinical stage ≥T2. Only 17% (25 of 145) of these patients received cisplatin‐based neoadjuvant chemotherapy. The renal function was adequate (CrCl > 60 ml/min) in 97 (67%) of these patients. Patients who received neoadjuvant chemotherapy had higher p0 rates (29% vs 8%) than patients who did not receive neoadjuvant therapy. Advanced patient age, comorbidities, concerns over toxicity of chemotherapy, and the modest nature of benefit from neoadjuvant chemotherapy may explain why this treatment is not often used. CONCLUSIONS: Despite level I evidence, neoadjuvant cisplatin‐based chemotherapies continue to be underutilized in the management of bladder cancer, even at a high‐volume tertiary center. A prospective evaluation of management choices, including the patient and physician factors involved in the use of perioperative cisplatin‐based chemotherapy in bladder cancer, is indicated. Cancer 2011. © 2010 American Cancer Society.Keywords
This publication has 25 references indexed in Scilit:
- Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the BladderJournal of Urology, 2008
- Taxanes as primary chemotherapy for early breast cancerCancer, 2008
- Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urotheliumCancer Treatment Reviews, 2008
- Low Incidence of Perioperative Chemotherapy for Stage III Bladder Cancer 1998 to 2003: A Report From the National Cancer Data BaseJournal of Urology, 2007
- Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 TrialEuropean Urology, 2007
- Bladder cancer: Epidemiology, staging and grading, and diagnosisUrology, 2005
- Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis CollaborationEuropean Urology, 2005
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerThe New England Journal of Medicine, 2003
- Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysisThe Lancet, 2003
- Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinomaCancer, 1997